| 摘要 |
A somatostatin agonist, e.g., an agonist with selectivity for an SSTR can be used to downregulate IGF and GH levels. The agonist can be used to treat disorders such as diabetic retinopathy, diabetic neuropathy, a neurodegenerative disorder such as Huntington's disease, obesity. Agonists, alone or in combination, that modulate at least two SSTR subtypes can be used. |
